<DOC>
	<DOC>NCT00140725</DOC>
	<brief_summary>This is a single-centre prospective randomised study comparing the virological and histological response of HBV infection to lamivudine in combination with interferon versus lamivudine alone.</brief_summary>
	<brief_title>Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion criteria: Untreated chronic hepatitis B patients with evidence of HBV replication as documented by serum HNVDNA positive within 3 months prior to entry and serum HBeAg positive at screening. Documented presence of abnormal alanine aminotransferase (ALT) (1.3 5X upper limit normal (ULN)) within 1 month prior to entry and signs of compensated liver disease. Exclusion criteria: Patients with any cause for liver disease other than chronic hepatitis B and evidence or history of decompensated liver disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>HBeAg-positive</keyword>
	<keyword>chronic</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>lamivudine</keyword>
	<keyword>seroconversion</keyword>
	<keyword>Chronic Hepatitis B</keyword>
</DOC>